For the last few years, the peptide community has lived in a “gray market.” In 2023, the FDA moved dozens of popular peptides into “Category 2,” a restrictive designation that effectively banned compounding pharmacies from producing them. This forced many patients toward unregulated “research only” websites with zero quality oversight.
That era appears to be ending.
In a recent appearance on the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. sent shockwaves through the health world by announcing a major policy reversal. Kennedy described the 2023 restrictions as overreach, stating, “We created the gray market,” and pledged to restore legal access to approximately 14 key peptides.
His goal is simple: move these substances back into regulated U.S. compounding pharmacies where they can be tested for purity and administered under medical supervision.
To make good on this promise, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) has officially scheduled a high-stakes meeting for July 23–24, 2026. During this session, they will review seven of the most in-demand peptides for inclusion on the 503A Bulk Drug Substances List.
If approved, these will move to Category 1, meaning Viva Wellness Center and other clinics can once again provide them legally and safely.
The FDA has split the review into two days. Here is the list of peptides rumored and confirmed for this first wave of re-entry:
Day 1 (July 23): Recovery & Metabolism
Day 2 (July 24): Brain & Longevity
The return of these peptides to licensed compounding pharmacies means transparency. You will no longer have to wonder if a vial from a “research” site contains heavy metals or the wrong dosage. Instead, you’ll have access to pharmaceutical-grade peptides, prescribed by a doctor and verified by a regulated lab.
En Centro de bienestar Viva, we are monitoring the July PCAC meetings closely. As these therapies return to legal compounding status, we will be among the first to offer them in a safe, clinical environment.
Don’t navigate the “gray market” alone. Schedule a consultation today to discuss your health goals and be the first to know when our 2026 peptide programs officially launch.
